A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for High-risk Patients With Chronic Lymphocytic Leukemia Following First-line Therapy

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for High-risk Patients With Chronic Lymphocytic Leukemia Following First-line Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology AssociationaResults of pooled data from 3 phase III trials (CLLM1, CONTINUUM, ORIGIN) presented at the 23rd Congress of the European Haematology Association.
    • 05 Jun 2018 Results of pooled data from 3 phase III trials (CLLM1, CONTINUUM, ORIGIN), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 09 May 2018 Planned End Date changed from 1 Jul 2021 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top